Skip to content
Summer 2026 · 26% off every plan with SUMMER26 See pricing
Optionomics
VHC · 10-Q filed August 14, 2026

VHC earnings analysis

What we found in VHC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.

Our reading of the filing · Free to read, no account needed

VirnetX produced no revenue in Q2 2026, with diluted EPS worsening to $(1.20) from $(0.99) year over year and net loss rising to $4.527 million. Operating cash burn remained substantial at $7.617 million for the first six months, reducing cash and cash equivalents to $13.090 million and prompting a going-concern disclosure. Although the company has a $20 million S-3 financing shelf, the filing provides no revenue or EPS guidance and indicates that additional capital or revenue will be needed to sustain operations.

What stood out

The parts that mattered.

Pulled out of the filing itself, with the figures the company reported.

Revenue Remained Zero
Revenue was $0 for the quarter, down from $48 thousand in the prior-year quarter and unchanged from $0 in the immediately preceding quarter. The company reported one operating segment.
EPS and Net Loss Worsened
Diluted EPS deteriorated to $(1.20) from $(0.99) year over year and $(1.16) in Q1 2026. Net loss increased to $4.527 million from $3.621 million in Q2 2025.
SG&A Drove Expense Growth
Operating expenses increased 16.5% to $4.652 million from $3.992 million year over year. SG&A rose $749 thousand to $3.526 million, driven by $388 thousand of higher legal expense, $362 thousand of higher equity compensation, and $395 thousand of higher travel expense.
Liquidity Position Deteriorated
Cash and cash equivalents declined to $13.090 million from $15.548 million at December 31, 2025, while working capital was $11.847 million. Short-term investments declined to approximately $799 thousand from $5.979 million.
Operating Cash Burn Increased
Six-month operating cash flow was negative $7.617 million, compared with negative $6.832 million in the prior-year period. Capital expenditures were only $8 thousand, indicating that cash use was overwhelmingly operating-related.
Financing Capacity Established
Management secured an effective Form S-3 shelf registration covering up to $20 million of securities on June 2, 2026, providing a potential financing source.
What to watch

And the other side of it.

The offsets in the same document — the things a summary that only listed the good news would have left out.

Going-Concern Uncertainty
The company disclosed substantial doubt about its ability to continue as a going concern because existing liquid resources are projected to be insufficient for the twelve months following issuance. It reported a six-month net loss of $8.881 million and an accumulated deficit of $231.776 million.
Potential Dilutive Financing
Management stated that additional capital may be needed and that financing may occur through equity offerings. The effective Form S-3 permits offerings of up to $20 million, creating potential dilution and financing risk.
Commercialization and Revenue Risk
Revenue was $0 in Q2 2026 and the company reported a six-month net loss of $8.881 million. Management cautioned that additional revenue cannot be assured or secured in sufficient quantity and that long, unpredictable sales cycles may exhaust financial resources before significant revenue is generated.
Costs Rising Without Revenue
SG&A increased to $3.526 million from $2.777 million year over year, including $388 thousand of higher legal expense and $362 thousand of higher equity compensation, while revenue remained $0.
Equity Dilution Exposure
As of June 30, 2026, the company had 685,339 outstanding options, including 218,337 vested options, and 1,133,720 shares available for grant under its equity plan. Future awards or exercises could dilute existing holders.
The numbers

What they reported.

What the company itself reported, taken out of the document.

Earnings per share
$-1.2
Segment
Single reportable segment; revenue was $0 for the three months ended June 30, 2026 versus $48 thousand in the prior-year quarter.
Guidance

What they said about what is next.

No quantitative revenue or EPS guidance was provided. Management expects the full-year effective tax rate to be 0%, while stating that existing liquid resources are projected to be insufficient to sustain operations for twelve months from the financial statement issuance date.

How we read the filing overall

The filing reads worse than the one before it.

One reading of one document. It is not advice, and it is not a forecast.
Earlier filings

What came before.

10-Q · May 15, 2026
VirnetX Holding Corporation reports no revenue for Q1 2026, consistent with Q1 2025 results. The company incurred a net loss of $4.4 million, which is an increase from a loss of $3.7 million a year ago, reflecting…
10-K · March 24, 2026
VirnetX (VHC) shows a clear revenue pickup in 2025 after immaterial 2024 results, driven by government/subcontract activity and early commercial product deployments (VirnetX One™, Matrix™, War Room™). Despite the…
10-Q · November 14, 2025
VirnetX reported Q3 revenue of $58,000 (vs $48,000 in prior quarter and $2,000 a year ago) with a GAAP net loss of $4,348 and diluted loss per share of $(1.18). Operating loss for the quarter was $(4,644) (versus…
10-Q · August 12, 2025
VirnetX reported a substantial increase in revenue for Q2 2025, generating $48,000, compared to just $1 in Q2 2024. However, the company continued to incur significant losses, with a diluted EPS of -$0.99, an…

This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.

Read the next one first.

We read every filing VHC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.

Cancel anytime · Month to month · Switch tiers whenever